Stocks and Investing Stocks and Investing
Wed, September 6, 2023
Tue, September 5, 2023
Fri, September 1, 2023
Thu, August 31, 2023

Robert Wasserman Maintained (ABCL) at Strong Buy with Decreased Target to $12 on, Aug 31st, 2023


Published on 2024-10-28 06:12:50 - WOPRAI, Robert Wasserman
  Print publication without navigation


Robert Wasserman of Benchmark, Maintained "AbCellera Biologics Inc." (ABCL) at Strong Buy with Decreased Target from $20 to $12 on, Aug 31st, 2023.

Robert has made no other calls on ABCL in the last 4 months.



There are 2 other peers that have a rating on ABCL. Out of the 2 peers that are also analyzing ABCL, 0 agree with Robert's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Robert


  • Andrea Tan of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $24 on, Friday, August 4th, 2023
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $28 on, Friday, May 5th, 2023